Home > Insider Trading > Filing (0000891839-20-000084)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1205922	Vaccinex Inc.	VCNX	Pharmaceutical Preparations (2834)	161603202

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1268239	Albert Friedberg	181 Bay Street Suite 250 Toronto A6 M5J 2T3		Yes	No	Yes	No
1678258	Fcmi Parent Co.	181 Bay Street Suite 250 Toronto A6 M5J 2T3		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-27	4,000	$4.18	7,625,601	No	4	P	Indirect	By FCMI Parent Co.
Common Stock	Acquisiton	2020-03-30	5,000	$4.06	7,630,601	No	4	P	Indirect	By FCMI Parent Co.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By FCMI Parent Co.
No	4	P	Indirect	By FCMI Parent Co.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	439,555	Direct
Common Stock	37,633	Indirect	By Pan-Atlantic Bank & Trust Ltd.
Common Stock	583,333	Indirect	By Global Macro Hedge Fund Ltd.

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Option (Right to Acquire)	$0.00			1,180,051	21,475,000	Indirect
Common Stock	Option (Right to Acquire)	$0.00			967,983	9,679,833	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
	1,180,051	21,475,000	Indirect
	967,983	9,679,833	Indirect

Footnotes

Mr. Friedberg is the majority owner of Pan Atlantic Bank & Trust Ltd. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Mr. Friedberg possesses voting and dispositive power over the reported securities and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by FCMI Parent Co. on January 23, 2019.
Mr. Friedberg is the majority owner, a director and the president of FCMI Parent Co. and disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Partnership interests in VX3 (DE) LP, or VX3, which are exchangeable into shares of Common Stock on a 1-for-0.05495 basis at the holder's option. On August 13, 2018, FCMI Parent Co. entered into an exchange agreement with the Issuer and the other partners of VX3 that provides each VX3 partner the right to exchange all, but not less than all, of its partnership interests in VX3 for shares of Common Stock. The option has no expiration date.
Limited partnership units of Vaccinex Products, LP, which are exchangeable into shares of Common Stock on a 1-for-10 basis at the holder's option.
FCMI Financial Corp. is a wholly-owned subsidiary of FCMI Parent Co. Mr. Friedberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interests therein.